ES2477882T3 - Probióticos, IgA secretora e infección - Google Patents

Probióticos, IgA secretora e infección Download PDF

Info

Publication number
ES2477882T3
ES2477882T3 ES09769156.2T ES09769156T ES2477882T3 ES 2477882 T3 ES2477882 T3 ES 2477882T3 ES 09769156 T ES09769156 T ES 09769156T ES 2477882 T3 ES2477882 T3 ES 2477882T3
Authority
ES
Spain
Prior art keywords
infection
probiotics
secretory iga
probiotic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09769156.2T
Other languages
English (en)
Other versions
ES2477882T5 (es
Inventor
Jalil Benyacoub
Blaise Corthesy
Stéphanie Blum-Sperisen
Laurent Favre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39832407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Publication of ES2477882T3 publication Critical patent/ES2477882T3/es
Application granted granted Critical
Publication of ES2477882T5 publication Critical patent/ES2477882T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición para usarse en el tratamiento, la reducción o la prevención de infecciones no víricas, comprendiendo la composición IgA secretora y al menos un probiótico, donde el probiótico se selecciona del grupo que consiste en Bifidobacterium y Lactobacillus, y donde la infección no vírica es una infección bacteriana.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
ES09769156.2T 2008-06-24 2009-06-16 Probióticos, IgA secretora e infección Active ES2477882T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08158833A EP2138187A1 (en) 2008-06-24 2008-06-24 Probiotics, secretory IgA and infection
EP08158833 2008-06-24
PCT/EP2009/057474 WO2009156307A1 (en) 2008-06-24 2009-06-16 Probiotics, secretory iga and infection

Publications (2)

Publication Number Publication Date
ES2477882T3 true ES2477882T3 (es) 2014-07-18
ES2477882T5 ES2477882T5 (es) 2018-11-07

Family

ID=39832407

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13188128.6T Active ES2616334T3 (es) 2008-06-24 2009-06-16 Probióticos, IgA secretora e infección
ES09769156.2T Active ES2477882T5 (es) 2008-06-24 2009-06-16 Probióticos, IgA secretora e infección

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13188128.6T Active ES2616334T3 (es) 2008-06-24 2009-06-16 Probióticos, IgA secretora e infección

Country Status (11)

Country Link
US (3) US9173937B2 (es)
EP (3) EP2138187A1 (es)
JP (1) JP2011525484A (es)
CN (2) CN105816875A (es)
AU (1) AU2009264423B2 (es)
BR (1) BRPI0914624B1 (es)
CA (1) CA2727303A1 (es)
ES (2) ES2616334T3 (es)
PL (2) PL2318047T3 (es)
PT (2) PT2318047E (es)
WO (1) WO2009156307A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138186A1 (en) * 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and inflammation
JP2012180304A (ja) * 2011-03-01 2012-09-20 Biseibutsu Kagaku Kenkyusho:Kk 鶏のカンピロバクター感染を制御するための飲料
EP3366143A1 (en) 2011-06-20 2018-08-29 H.J. Heinz Company Brands LLC Probiotic compositions and methods
DK2861242T3 (en) 2012-06-18 2018-10-29 Heinz Co Brands H J Llc GLUTEN RELATED DISORDERS
US9458230B2 (en) * 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
DK2994150T3 (da) 2013-05-10 2019-06-11 Heinz Co Brands H J Llc Probiotika og fremgangsmåde til anvendelse
US9468674B2 (en) 2013-09-24 2016-10-18 Wisconsin Alumni Research Foundation Methods of use of secretory IgA
CN104473292A (zh) * 2014-12-22 2015-04-01 威海百合生物技术股份有限公司 一种婴幼儿益生菌固体饮料
WO2018220416A1 (en) * 2017-05-31 2018-12-06 Compagnie Gervais Danone Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection
TWI731209B (zh) * 2018-01-09 2021-06-21 柯順議 益生菌組合物及其用途
JP2022529054A (ja) * 2019-04-17 2022-06-16 ニューテック・ベンチャーズ 持続性が強化された新規微生物を含む組成物、新規微生物とプレバイオティクスの相乗的組み合わせ、およびそのような微生物の分離方法
US20220296706A1 (en) * 2019-06-28 2022-09-22 Societe Des Produits Nestle S.A. COMPOSITIONS COMPRISING SECRETORY IgA AND PROBIOTICS
WO2021021746A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. NUTRITIVE COMPOSITIONS WITH SECRETED IgA, MILK FAT GLOBULE MEMBRANE COMPONENTS AND/OR BIFIDOBACTERIUM
WO2021062049A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Beneficial bacteria and secretory immunoglobulin a
WO2021219786A1 (en) 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
TWI823060B (zh) * 2021-02-26 2023-11-21 豐華生物科技股份有限公司 提升口腔免疫球蛋白a含量及抑制口腔病原菌之組成物及其用途
AU2022420738A1 (en) 2021-12-20 2024-05-30 Société des Produits Nestlé S.A. Secretory iga-biotic complexes and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5589233A (en) * 1978-12-28 1980-07-05 Shogo Nakano Preparation of additive for breeding of new born cattle
JP2968374B2 (ja) * 1991-05-16 1999-10-25 株式会社ヤクルト本社 ＩｇＡ産生促進剤
JPH06234647A (ja) * 1993-02-12 1994-08-23 Yakult Honsha Co Ltd ＩｇＡ産生促進剤およびその製造法
JP3269890B2 (ja) * 1993-08-25 2002-04-02 株式会社ヤクルト本社 ワクチンの効果増強剤及び効果増強食品
US5531988A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Bacteria and immunoglobulin-containing composition for human gastrointestinal health
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
US6616927B2 (en) * 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
AU2002339112B2 (en) * 2001-11-12 2007-10-11 Mars, Incorporated Foodstuff
US7842495B2 (en) * 2003-08-21 2010-11-30 Otsuka Pharmaceutical Co., Ltd. Lactic acid bacteria capable of stimulating mucosal immunity
JP5001830B2 (ja) * 2005-02-02 2012-08-15 株式会社明治 免疫賦活用組成物
AU2006246299B2 (en) * 2005-05-10 2013-10-24 Saputo Dairy Australia Pty Limited Immunoglobulin fraction and process therefor
EP1915174A1 (en) * 2005-08-19 2008-04-30 Unilever N.V. Food products comprising probiotic micro-organisms and antibodies
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2138186A1 (en) 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and inflammation
JP5589233B2 (ja) 2011-08-24 2014-09-17 株式会社 ｌｉｆｅ ｐａｒｋ． ｂｉｚ 消火器の基台

Also Published As

Publication number Publication date
CN102076361A (zh) 2011-05-25
WO2009156307A1 (en) 2009-12-30
US20160106834A1 (en) 2016-04-21
BRPI0914624A2 (pt) 2015-10-20
US9629908B2 (en) 2017-04-25
US9173937B2 (en) 2015-11-03
EP2318047A1 (en) 2011-05-11
EP2318047B1 (en) 2014-05-14
US20170281757A1 (en) 2017-10-05
EP2318047B2 (en) 2018-08-15
CN105816875A (zh) 2016-08-03
EP2138187A1 (en) 2009-12-30
PT2318047E (pt) 2014-06-24
CA2727303A1 (en) 2009-12-30
EP2700411A1 (en) 2014-02-26
AU2009264423A1 (en) 2009-12-30
PL2318047T3 (pl) 2014-10-31
JP2011525484A (ja) 2011-09-22
EP2700411B1 (en) 2016-12-28
BRPI0914624B1 (pt) 2021-11-09
PT2700411T (pt) 2017-03-29
ES2477882T5 (es) 2018-11-07
AU2009264423B2 (en) 2014-01-16
US20120014963A1 (en) 2012-01-19
ES2616334T3 (es) 2017-06-12
PL2700411T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
ES2477882T3 (es) Probióticos, IgA secretora e infección
ATE526836T1 (de) Nährstoffzusammensetzung mit probiotika
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
ES2523968T3 (es) Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas
ES2576642T3 (es) Prevención de infecciones oportunistas en sujetos inmunológicamente comprometidos
BR112018074795A2 (pt) novo uso médico de probióticos
ES2524432T3 (es) Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas
WO2016086209A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment of gastrointestinal disorders
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
BRPI1010637A2 (pt) suplementos nutricionais orais compreendendo probióticos
AR042313A1 (es) Composicion bacteriana y su uso para inmunomudulacion y prevencion de la enfermedad inflamatoria intestinal
AR107921A1 (es) Uso de probióticos en el tratamiento y/o la prevención de la enfermedad de la psoriasis
PE20190417A1 (es) Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
RS53136B (en) ACINETOBACTER TREATMENT WITH ALGINATE OLIGOMERS AND ANTIBIOTICS
MY171618A (en) Strain of lactobacillus as probiotic
AR069943A1 (es) Metodo para reducir la circunferencia abdominal mediante la administracion de una bacteria bifidobacterium
DK2101796T3 (da) Bacillus smithii stamme TBM112 MSCL P737 og anvendelse af endosporer deraf som probiotikum eller kosttilskud
CL2008003489A1 (es) Composicion de microcapsulas de copolimero lactico-co-glicolico (plga) o copolimero lactico co-glicolico y polietilenglicol (plga-peg) comprendiendo somatostatina o un analogo del mismo; y su uso para tratar y/o prevenir la diarrea.
PH12017502042A1 (en) Dietary supplement
AR095486A1 (es) Composición nutricional para el tratamiento de emesis idiopática crónica en felinos y canes
CL2009001511A1 (es) Formulacion farmaceutica que comprende cepas viables de lactobacillus acidophilus lpv 31 y l. plantarum lpm-01, la cual es util en la prevencion y/o tratamiento de infecciones urinarias y en mejorar la respuesta inmune en pacientes inmunocopromentidos.
CL2010001589A1 (es) Compuestos derivados de 3-ciano-pirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
CL2010001590A1 (es) Compuestos derivados de 3-(n-heterociclil)-pirrolidin-feniloxazolidinonas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de infecciones bacterianas
Tehrani et al. The effect of some lactobacillus species (probiotics) on biofilm inhibition in Enterococcus faecium